Robo4 vaccines induce antibodies that retard tumor growth

Angiogenesis

Volumn 18, Issue 1, 2015, Pages 83-95

  Zhuang, Xiaodong ^a   Ahmed, Forhad ^a   Zhang, Yang ^a   Ferguson, Henry J ^a   Steele, Jane C ^a   Steven, Neil M ^a   Nagy, Zsuzsanna ^a   Heath, Victoria L ^a   Toellner, Kai Michael ^a   Bicknell, Roy ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

ADCC; Cancer; Conjugate vaccines; Immunotherapy

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIBODY; CANCER VACCINE; CD8 ANTIGEN; FREUND ADJUVANT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; ROBO4 PROTEIN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; NERVE PROTEIN; PAPAIN; PRIMER DNA; RECOMBINANT VACCINE; ROBO4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER IMMUNIZATION; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR VASCULARIZATION; ADULT; AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE VECTOR; GENETICS; HEK293 CELL LINE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULAR GENETICS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POLYMERASE CHAIN REACTION; PROCEDURES; TUMOR CELL CULTURE;

ADULT; AMINO ACID SEQUENCE; ANIMALS; CHROMATOGRAPHY, AFFINITY; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC VECTORS; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NERVE TISSUE PROTEINS; PAPAIN; POLYMERASE CHAIN REACTION; RECEPTORS, IMMUNOLOGIC; TUMOR CELLS, CULTURED; VACCINES, SYNTHETIC;

EID: 84922098647     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-014-9448-z     Document Type: Article

References (49)

1. Mura M, Swain RK, Zhuang X, Vorschmitt H, Reynolds G, Durant S et al (2012) Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene 31(3):293–305
2. Matejuk A, Leng Q, Chou ST, Mixson AJ (2011) Vaccines targeting the neovasculature of tumors. Vasc Cell 3(1):7
3. Haller BK, Brave A, Wallgard E, Roswall P, Sunkari VG, Mattson U et al (2010) Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma. Oncogene 29(30):4276–4286
4. Huijbers EJ, Ringvall M, Femel J, Kalamajski S, Lukinius A, Abrink M et al (2010) Vaccination against the extra domain-B of fibronectin as a novel tumor therapy. FASEB J 24(11):4535–4544
5. Jarosz M, Jazowiecka-Rakus J, Cichon T, Glowala-Kosinska M, Smolarczyk R, Smagur A et al (2013) Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents. Gene Ther 20(3):262–273
6. Yoshikawa M, Mukai Y, Okada Y, Tsumori Y, Tsunoda S, Tsutsumi Y et al (2013) Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody. Blood 121(14):2804–2813
7. Grone J, Doebler O, Loddenkemper C, Hotz B, Buhr HJ, Bhargava S (2006) Robo1/Robo4: differential expression of angiogenic markers in colorectal cancer. Oncol Rep 15(6):1437–1443
8. Huminiecki L, Gorn M, Suchting S, Poulsom R, Bicknell R (2002) Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics 79(4):547–552
9. Seth P, Lin Y, Hanai J, Shivalingappa V, Duyao MP, Sukhatme VP (2005) Magic roundabout, a tumor endothelial marker: expression and signaling. Biochem Biophys Res Commun 332(2):533–541
10. Marlow R, Binnewies M, Sorensen LK, Monica SD, Strickland P, Forsberg EC et al (2010) Vascular Robo4 restricts proangiogenic VEGF signaling in breast. Proc Natl Acad Sci USA 107(23):10520–10525
11. Zhuang X, Cross D, Heath VL, Bicknell R (2011) Shear stress, tip cells and regulators of endothelial migration. Biochem Soc Trans 39(6):1571–1575
12. Kitamura D, Roes J, Kuhn R, Rajewsky K (1991) A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350(6317):423–426
13. Jung S, Rajewsky K, Radbruch A (1993) Shutdown of class switch recombination by deletion of a switch region control element. Science 259(5097):984–987
14. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272(5259):263–267
15. Pham HM, Arganaraz ER, Groschel B, Trono D, Lama J (2004) Lentiviral vectors interfering with virus-induced CD4 down-modulation potently block human immunodeficiency virus type 1 replication in primary lymphocytes. J Virol 78(23):13072–13081
16. Dwyer MA, Huang AJ, Pan CQ, Lazarus RA (1999) Expression and characterization of a DNase I-Fc fusion enzyme. J Biol Chem 274(14):9738–9743
17. Stura EA, Fieser CG, Wilson IA (1993) Crystallization of antibodies and antibody–antigen complexes. Immunomethods 3:164–179
18. Wang AC, Wang IY (1977) Cleavage sites of human IgG1 immunoglobulin by papain. Immunochemistry 14(3):197–200
19. Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H (1984) Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312(5994):548–551
20. Qin S, Cobbold S, Tighe H, Benjamin R, Waldmann H (1987) CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur J Immunol 17(8):1159–1165
21. Garside P, Ingulli E, Merica RR, Johnson JG, Noelle RJ, Jenkins MK (1998) Visualization of specific B and T lymphocyte interactions in the lymph node. Science 281(5373):96–99
22. Suchting S, Heal P, Tahtis K, Stewart LM, Bicknell R (2005) Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration. FASEB J 19(1):121–123
23. Attia MA, Weiss DW (1966) Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res 26(8):1787–1800
24. Toellner KM, Luther SA, Sze DM, Choy RK, Taylor DR, MacLennan IC et al (1998) T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J Exp Med 187(8):1193–1204
25. Huijbers EJ, Femel J, Andersson K, Bjorkelund H, Hellman L, Olsson AK (2012) The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund’s in a cancer vaccine targeting ED-B–a prerequisite for clinical development. Vaccine 30(2):225–230
26. Laitinen L (1987) Griffonia simplicifolia lectins bind specifically to endothelial cells and some epithelial cells in mouse tissues. Histochem J 19(4):225–234
27. Tyagi N, Roberts AM, Dean WL, Tyagi SC, Lominadze D (2008) Fibrinogen induces endothelial cell permeability. Mol Cell Biochem 307(1–2):13–22
28. Hariharan K, Braslawsky G, Black A, Raychaudhuri S, Hanna N (1995) The induction of cytotoxic T cells and tumor regression by soluble antigen formulation. Cancer Res 55(16):3486–3489
29. Toellner K-M, Gulbranson-Judge A, Taylor DR, Sze DM-Y, MacLennan ICM (1996) Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation. J Exp Med 183(5):2303–2312
30. Toellner K-M, Luther SA, Sze DM, Choy RK, Taylor DR, MacLennan IC et al (1998) T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J Exp Med 187(8):1193–1204
31. Siemann DW (2011) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev 37(1):63–74
32. Huminiecki L, Bicknell R (2000) In silico cloning of novel endothelial-specific genes. Genome Res 10(11):1796–1806
33. Park KW, Morrison CM, Sorensen LK, Jones CA, Rao Y, Chien CB et al (2003) Robo4 is a vascular-specific receptor that inhibits endothelial migration. Dev Biol 261(1):251–267
34. Sheldon H, Andre M, Legg JA, Heal P, Herbert JM, Sainson R et al (2009) Active involvement of Robo1 and Robo4 in filopodia formation and endothelial cell motility mediated via WASP and other actin nucleation-promoting factors. FASEB J 23(2):513–522
35. Jones CA, London NR, Chen H, Park KW, Sauvaget D, Stockton RA et al (2008) Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat Med 14(4):448–453
36. Koch AW, Mathivet T, Larrivee B, Tong RK, Kowalski J, Pibouin-Fragner L et al (2011) Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B. Dev Cell 20(1):33–46
37. Okada Y, Jin E, Nikolova-Krstevski V, Yano K, Liu J, Beeler D et al (2008) A GABP-binding element in the Robo4 promoter is necessary for endothelial expression in vivo. Blood 112(6):2336–2339
38. Nagayama H, Matsumoto K, Isoo N, Ohno H, Takahashi N, Nakaoka T et al (2010) Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer. Clin J Gastroenterol 3(6):307–317
39. Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96(12):1788–1795
40. Clark AJ, Butowski NA, Chang SM, Prados MD, Clarke J, Polley MY et al (2011) Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg 114(6):1609–1616
41. Boles KS, Schmieder AH, Koch AW, Carano RA, Wu Y, Caruthers SD et al (2010) MR angiogenesis imaging with Robo4- vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB J 24(11):4262–4270
42. Johansson J, Ledin A, Vernersson M, Lovgren-Bengtsson K, Hellman L (2004) Identification of adjuvants that enhance the therapeutic antibody response to host IgE. Vaccine. 22(21–22):2873–2880
43. Ringvall M, Huijbers EJ, Ahooghalandari P, Alekseeva L, Andronova T, Olsson AK et al (2009) Identification of potent biodegradable adjuvants that efficiently break self-tolerance—a key issue in the development of therapeutic vaccines. Vaccine 28(1):48–52
44. Anderson P (1983) Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197. Infect Immun 39(1):233–238
45. Savelyeva N, Shipton M, Suchacki A, Babbage G, Stevenson FK (2011) High-affinity memory B cells induced by conjugate vaccines against weak tumor antigens are vulnerable to nonconjugated antigen. Blood 118(3):650–659
46. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6(4):443–446
47. Parra C, Gonzalez JM, Castaneda E, Fiorentino S (2005) Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice. Biomedica 25(1):110–119
48. Niederer HA, Clatworthy MR, Willcocks LC, Smith KG (2010) FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus. Ann NY Acad Sci 1183:69–88
49. Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L et al (2013) IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Investig 123(4):1457–1474